Correlation Between Hyperhomocysteinemia and Outcomes of Patients With Acute Myocardial Infarction

被引:15
作者
Ma, Yi [1 ]
Li, Li [1 ]
Geng, Xue-Bin [1 ]
Hong, Ye [1 ]
Shang, Xiao-Ming [1 ]
Tan, Zheng [1 ]
Song, Yu-Xin [1 ]
Zhao, Guo-Yu [1 ]
Zhao, Bi-Qiong [1 ]
Tian, Mei-Rong [1 ]
机构
[1] Hebei Med Univ, Tangshan Affiliated Clin Hosp, Dept Cardiovasc Med, Tangshan 063000, Hebei, Peoples R China
关键词
hyperhomocysteinemia; outcome; acute myocardial infarction; independent predictor; PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; RISK-FACTOR; VASCULAR-DISEASE; MORTALITY; HOMOCYST(E)INE; ASSOCIATION; WOMEN; MEN;
D O I
10.1097/MJT.0000000000000130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Overwhelming clinical and epidemiological studies have identified elevated plasma total homocysteine (Hcy) as new important risk factor for atherosclerotic vascular disease. But the relationship between outcome and hyperhomocysteinemia in patients with acute myocardial infarction (AMI) has been rarely reported. This study aimed to evaluate the association between hyperhomocysteinemia and short-term outcomes of patients with AMI. Eight hundred five patients were divided into high Hcy level group (group H: N = 457) and low Hcy level group (group L: N = 348) according to the plasma Hcy levels of 15 mmol/L. The comparisons were made between 2 groups in the following aspects: sex, hypertension, diabetes, hyperlipidemia, the time for symptom from onset to percutaneous coronary intervention, homoccyteine, creatine phosphokinase isoenzyme (creatine kinase myocardial band), and the incidence of 30-day adverse events. The incidences of heart failure, cardiac rupture, death, and the total adverse cardiovascular events were statistically significantly higher in group H than in group L. But the incidence of postoperative angina pectoris and reinfarction was similar between groups. The results of logistic regression showed that the incidence of 30-day adverse events was closely related to the age and the level of Hcy. An elevated plasma total Hcy level in patients with AMI experienced pemutaneous coronary intervention may be related to the short-term outcomes. An elevated high plasma Hcy level also seems to be an independent predictor of 30-day cardiovascular events in patients with AMI.
引用
收藏
页码:E1464 / E1468
页数:5
相关论文
共 25 条
[1]   RELATION OF SERUM HOMOCYSTEINE AND LIPOPROTEIN(A) CONCENTRATIONS TO ATHEROSCLEROTIC DISEASE IN A PROSPECTIVE FINNISH POPULATION-BASED STUDY [J].
ALFTHAN, G ;
PEKKANEN, J ;
JAUHIAINEN, M ;
PITKANIEMI, J ;
KARVONEN, M ;
TUOMILEHTO, J ;
SALONEN, JT ;
EHNHOLM, C .
ATHEROSCLEROSIS, 1994, 106 (01) :9-19
[2]   Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women [J].
Bostom, AG ;
Silbershatz, H ;
Rosenberg, IH ;
Selhub, J ;
D'Agostino, RB ;
Wolf, PA ;
Jacques, PF ;
Wilson, PWF .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1077-1080
[3]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[4]  
Ceperkovic Zoran, 2006, Med Pregl, V59, P143, DOI 10.2298/MPNS0604143C
[5]   Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022
[6]  
Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004
[7]  
Effychiou C, 2012, HELL J CARDIOL, V53, P189
[8]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375
[9]   Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial [J].
Evans, RW ;
Shaten, BJ ;
Hempel, JD ;
Cutler, JA ;
Kuller, LH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) :1947-1953
[10]   Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].
Graham, IM ;
Daly, LE ;
Refsum, HM ;
Robinson, K ;
Brattstrom, LE ;
Ueland, PM ;
PalmaReis, RJ ;
Boers, GHJ ;
Sheahan, RG ;
Israelsson, B ;
Uiterwaal, CS ;
Meleady, R ;
McMaster, D ;
Verhoef, P ;
Witteman, J ;
Rubba, P ;
Bellet, H ;
Wautrecht, JC ;
deValk, HW ;
Luis, ACS ;
ParrotRoulaud, FM ;
Tan, KS ;
Higgins, I ;
Garcon, D ;
Medrano, MJ ;
Candito, M ;
Evans, AE ;
Andria, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781